# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹7,589 Cr** Q3 (+8%) * **EBITDA Margin:** **25%** Q3 (ex-other income) · **>25%** H1 * **Gross Margin:** **67%** Q3 (post-material cost), down 160–170 bps QoQ * **PAT:** **₹1,351 Cr** Q3 (8% of sales) * **Net Cash Balance:** **₹9,901 Cr** (debt: ₹467 Cr) ## B. Revenue Growth * **Record Top-Line Performance:** Highest-ever quarterly revenue achieved, reflecting sustained market penetration and demand resilience. ## C. EBITDA Margin * **Margin Resilience Amid Headwinds:** EBITDA margin held firm despite adverse product mix, lower prices for **lenalidomide**, and higher **R&D material costs**. * **Temporary Tailwinds Fading:** First-half margin strength partially inflated by **one-time Revlimid benefit**, leading to wider full-year guidance. * **Core Margins Stable:** No structural erosion in gross margins despite sequential decline, signaling underlying profitability integrity. ## D. Cash Flow & Debt * **Strong Liquidity Profile:** Robust free cash flow generation maintained net cash position near **₹10,000 Cr** despite **>₹400 Cr** in outflows and dividends. * **Cost Inflation Pressures:** Total expenses rose 11% YoY, driven by elevated **R&D spend, litigation costs, and sales-aligned marketing investments**. --- # 2. Therapy & Product Performance ## A. Key Figures * **Chronic Therapy Growth:** **10%** anti-diabetes · **13%** cardiac · **17%** urology · **18%** dermatology (vs. 8% market) * Chronic Care Mix: 61.8% of total sales (up YoY) * **Unit Sales Volume:** **2 billion plus** units (largest pharma by volume in IPM) * Chronic Care CAGR: 16.4% (MAT Sep '21–'25), with revenues almost doubling * **Lanreotide Market Share:** **22%** (MAT Aug '25) * **Brands in ₹100 Cr+ Club:** **29** total (up 4 new additions) * **IPM Top 300 Brands:** **22** Cipla brands represented ## B. Chronic Care & Therapy Trends * **Outperformance in Key Therapies:** Chronic care segments significantly outpaced market growth, led by strong momentum in urology, dermatology, and respiratory. * **Strategic Shift Confirmed:** Rising chronic therapy mix to **8%** reflects sustained pivot toward high-growth, science-led chronic and lifestyle disease portfolios. * **Respiratory Leadership Intact:** Foracort ranked #1 brand in IPM; triple-combo products gaining traction amid seasonal tailwinds and continued investment. * **Recovery Underway:** India business rebounding in Q2 after Q1 respiratory softness and restructuring, with volume leadership providing scale advantage. ## C. New Product Launches & Pipeline * **Tirzepatide Launch Prep Complete:** Dedicated field force deployed; Yurpeak (with Lilly) marks strategic entry into obesity and diabetes, targeting strong uptake in Tier 2/3 towns. * **Biosimilar & Innovation Milestone:** U.S. launch of **filgrastim**, first biosimilar, and upcoming launches like Elbicip, Aprela, and Rizontem reinforce science-led, diversified pipeline. * **Launch Momentum Continues:** Six new products in quarter; anti-infective and CNS portfolio expanded with Huena, ZEMDRI, Doloneuron, and Zolsoma. * **Abraxane & Nanoparticle Paclitaxel:** Abraxane recovering after launch headwinds; nanoparticle paclitaxel share now increasing from negligible base. ## D. Brand & Portfolio Growth * **Portfolio Depth Expands:** Addition of four ₹100 Cr+ brands and 22 in IPM Top 300 underscores broadening market footprint and brand equity. * **Licensing Model De-risked:** Yurpeak financial structure follows standard supply-margin model; Cipla bears marketing costs but retains full promotional control. * **Beyond Respiratory:** Strategic expansion into obesity, CNS, and urology reflects alignment with chronic lifestyle trends, reducing reliance on any single franchise. --- # 3. Geography & Market Mix ## A. Key Figures * **North America Revenue:** **$233 Mn** (quarterly) * **EMEU Revenue:** **$110 Mn** (record quarterly, +15% YoY) * **One Africa Growth:** **+5% YoY** (USD) · **South Africa:** **+6% YoY** (ZAR) * **India Business Growth:** **+7% YoY** (Q2 FY26) ## B. North America Market Position * **Market Leadership Achieved:** Cipla is now the **number one player** in the U.S. albuterol MDI category with **22% market share**, supported by strong patient adoption and supply of over **5 crore inhalers** since launch. * **Significant Share Upside Potential:** Market dynamics suggest Cipla could capture up to **30% share** in a scenario where the innovator retains 70%, contingent on competitor filings and regulatory timing. ## C. India Business Trends * **Growth Reacceleration Underway:** One-India business delivered **7% YoY growth** in Q2, reflecting improving momentum despite prior-year trade disruptions and current-seasonality headwinds. * **Strategic Patience Emphasized:** Management affirms focus on scaling the **generic business** across key markets and supports new leadership in shaping strategy, signaling continuity in competitive positioning. ## D. Africa & EMEU Growth * **Record Performance in EMEU:** Business achieved **highest-ever quarterly revenue**, driven by strength in DTM and B2B channels, underpinned by deep penetration and **stable margins**. * **Resilient Africa Growth:** Trade generics recovered swiftly from brief GST-related disruptions, delivering **strong double-digit growth** on the back of new launches and distribution execution. * **South Africa Outpaces Market:** Private market secondary growth of **2%** outperformed a **7% market contraction**, driven by tenders, new products, and therapy-level gains. --- # 4. R&D & Pipeline Progress ## A. Key Figures * R&D Spend: INR 539 Cr (Qtr) (~7.1% of revenue) · 50 bps above annual plan ## B. R&D Strategy & Drivers * **Elevated Investment:** R&D spend elevated due to **new programs** and acceleration in filings, not preponement, with H2 spending to remain high. * **Strategic Focus:** Increased investment concentrated in **complex generics**—respiratory, oligonucleotides, and peptides—aligning with core capabilities. ## C. GLP-1 & Obesity Pipeline * **Tirzepatide Leadership:** Positioned as **first-mover** in India with **exclusive partnership** and **nationwide scale**, aiming to shape market ahead of mid-2030s patent expiry. * **Market Differentiation:** **Clinical and scientific superiority** of tirzepatide supports distinct positioning; early **physician segmentation** indicates coexistence with semaglutide. * **Launch Timing & Evaluation:** Semaglutide launch pending approval (now expected **beyond March–April**) and strategic assessment, including **focus on tirzepatide** and competitive landscape. ## D. Biosimilar Development * **Portfolio Expansion:** Plans to grow biosimilar pipeline via **internal development and partnerships**, responding to FDA guidance and market opportunity. * **Pipeline Depth:** **2–3 internally developed biosimilars** in U.S. pipeline, with partnered candidates, set to expand over next **2–3 years**. * **Nanoparticle Opportunity:** Nanoparticle paclitaxel seen as **high-potential future driver** with strong early uptake. --- # 5. Manufacturing & Supply Chain ## A. CMO Dependencies * **External Sourcing Model:** GLP-1 API and fill-finish operations are fully outsourced to CMOs, with no in-house manufacturing currently in place. * **Strategic Evaluation:** Company is assessing potential to internalize fill-finish for select product lines over time, signaling long-term vertical integration intent. * **Lilly Partnership Structure:** Collaboration relies entirely on Lilly’s supply chain, bypassing internal API or fill-finish capabilities. * **Labor Cost Disparity:** U.S. manufacturing costs are meaningfully higher than India’s, driven primarily by **significantly elevated labor expenses** for operations and quality roles. * **Automation Mitigant:** Respiratory facilities leverage high automation, reducing labor dependency and partially narrowing the U.S.-India cost gap. ## B. U.S. Facility Status * **FDA Inspection Status:** Bommasandra (Bengaluru) facility underwent a VAI-qualified FDA inspection in Q1 FY’26, with a reinspection anticipated. * **Kemwell Pre-Approval Progress:** Successful pre-approval inspection completed, alongside technology transfer for a **non-biologic fill-finish product**, though specific details remain undisclosed. ## C. Capacity Expansion * **Supply Chain Resilience:** Current CMO and partnership networks, including Lilly, provide sufficient capacity to meet projected demand. --- # 6. Pricing & Regulatory Risks ## A. Key Figures * **Revlimid Revenue Trend:** **Near-zero to minimal contribution expected in Q3** (post-patent expiry) ## B. Revlimid Impact * **Planned Revenue Decline:** Revlimid’s contribution declining as anticipated, with near-zero impact expected in Q3 following January patent expiry, consistent with guidance. * **No Material Downside Surprise:** Current performance aligns with internal and consensus expectations; full-year margin impact already embedded in outlook. * **FY26 Revenue Not Guided for 50% Drop:** No official projection of >50% YoY decline in Revlimid sales; historical volume trends remain stable. ## C. FDA & Litigation Risk * **QVAR Launch Undisclosed:** Generic QVAR launch timing remains confidential due to active litigation, restricting forward-looking commentary. * **Lanreotide Competition Absent:** No near-term threat of new competition in the lanreotide market identified. --- # 7. Guidance & Outlook ## A. Key Figures * U.S. Revenue Guidance: ~$1.0B (directional target for next year, ±$50M based on launch timing) **B. S. Revenue Guidance:** **$1.0B** (target for next year, ±$50M based on launch timing) * **EBITDA Margin Guidance (FY26):** **17.75%–24%** (revised down from 25%–25%) ## B. FY26 Revenue Target * **India Growth Rebound:** On track to match or exceed market growth in Q3 as operational stability improves, with market expansion supported by GLP-1 agonist demand. * **North America Trajectory:** Base business expected to grow QoQ in Q3; upcoming launches poised to offset Revlimid decline over next four quarters, pending FDA approvals. * **Global Momentum:** $1B U.S. revenue target remains achievable on a run-rate basis if regulatory approvals are timely; EMEU to sustain growth and margins via core market penetration. ## C. Margin Forecast * **Margin Pressure Drivers:** Revised EBITDA guidance reflects higher-than-expected R&D spend, absence of Revlimid benefits, and seasonal respiratory uncertainty. * **H2 R&D Ramp-Up:** R&D investment accelerating beyond Q2’s 5% of sales, weighing on margins despite Q4 seasonal recovery and new product launches. * **Forward Clarity Pending:** FY27 margin outlook to be communicated next quarter post-budgeting; current focus on managing investment cycle and execution risk. ## D. Launch Timelines * **Respiratory & Peptide Pipeline:** Four key assets targeted for launch by CY26, including generic Advair (Q4’26) and three peptides (e.g., liraglutide), with reduced regulatory risk via U.S.-filed submissions. * **GLP-1 Commercial Push:** Tirzepatide launch prioritized to capture high-growth diabetes/obesity market; timing dependent on approval velocity. * **Seasonal Dynamics:** Q3 typically strongest (respiratory season), Q4 weakest—impacting both revenue and margin expectations despite new launches.